ERBB2 and breast carcinoma: The phase II SAFIR02-BREAST IMMUNO trial evaluated the use of checkpoint inhibitor monotherapy as a maintenance treatment, comparing the anti-PD-1 antibody durvalumab to continued chemotherapy in metastatic HER2-negative breast cancer patients who did not progress after 6–8 cycles of chemotherapy, and did not have actionable genetic mutations.